• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Moves Higher; US New Home Sales Fall In February

    3/25/24 11:54:41 AM ET
    $ABBV
    $AKAN
    $CYTO
    $FSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ABBV alert in real time by email

    U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday.

    The Dow traded down 0.22% to 39,389.17 while the NASDAQ fell 0.15% to 16,410.10. The S&P 500 also fell, dropping, 0.16% to 5,226.01.

    Check This Out: Progress Software Likely To Report Lower Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

     

    Leading and Lagging Sectors

     

    Energy shares jumped by 1% on Monday.

    In trading on Monday, communication services shares fell by 0.5%.

     

    Top Headline

     

    Sales of new single-family houses in the U.S. fell by 0.3% from the prior month to an annualized rate of 662,000 in February, compared to market estimates of 675,000.

     

    Equities Trading UP

     

    Landos Biopharma, Inc. (NASDAQ:LABP) shares shot up 170% to $21.62. AbbVie Inc. (NYSE:ABBV) and Landos Biopharma, reported a definitive agreement under which AbbVie will acquire Landos.

    Shares of Nkarta, Inc. (NASDAQ:NKTX) got a boost, surging 24% to $11.04 after the company priced $240 million underwritten offering.

    Altamira Therapeutics Ltd. (NASDAQ:CYTO) shares were also up, gaining 57% to $2.70 after the company announced a collaboration with Univercells Group on nanoparticle-delivered mRNA vaccines.

     

    Equities Trading DOWN

     

    Sintx Technologies, Inc. (NASDAQ:SINT) shares dropped 49% to $0.0472 after the company announced pricing of a $1.3 million public offering of common stock.

    Shares of Akanda Corp. (NASDAQ:AKAN) were down 39% to $0.1483 after the company announced pricing of underwritten public offering.

    Fisker Inc. (NYSE:FSR) was down, falling 28% to $0.0897 after the company announced it received notice from the large automaker with which the company had been in negotiations for a potential transaction that the automaker terminated the negotiations.

    Also Check This Out: Wall Street's Most Accurate Analysts Say Buy These 3 Energy Stocks With Over 5% Dividend Yields

     

    Commodities

     

    In commodity news, oil traded up 1.7% to $82.02 while gold traded up 0.8% at $2,177.40.

    Silver traded up 0.4% to $24.95 on Monday, while copper rose 0.5% to $4.0275.

     

    Euro zone

     

    European shares were mostly higher today. The eurozone’s STOXX 600 rose 0.13%, London’s FTSE 100 fell 0.07% while Spain’s IBEX 35 Index rose 0.30% The German DAX rose 0.41% French CAC 40 rose 0.12% while Italy’s FTSE MIB Index rose 0.85%.

    Spanish industrial producer prices declined by 8.2% year-over-year in February versus a revised 3.9% decline in the prior month.

     

    Asia Pacific Markets

     

    Asian markets closed lower on Monday, with Japan’s Nikkei 225 dipping 1.16%, Hong Kong’s Hang Seng Index falling 0.16% and China’s Shanghai Composite Index falling 0.71%.

    The index of leading economic indicators in Japan was revised lower to 109.5 in January versus a preliminary reading of 109.9, while index of coincident economic indicators was revised higher to 112.1 in January versus the flash reading of 110.2. The annual inflation rate in Malaysia accelerated to 1.8% in February from 1.5% a month ago.

     

    Economics

     

    The Chicago Fed National Activity Index rose to a three-month high level of 0.05 in February versus a revised reading of -0.54 in the prior month.

    Sales of new single-family houses in the U.S. fell by 0.3% from the prior month to an annualized rate of 662,000 in February, compared to market estimates of 675,000.

    Now Read This: Top 2 Real Estate Stocks That May Rocket Higher In March

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $AKAN
    $CYTO
    $FSR

    CompanyDatePrice TargetRatingAnalyst
    AbbVie Inc.
    $ABBV
    2/25/2026$260.00Outperform
    RBC Capital Mkts
    AbbVie Inc.
    $ABBV
    2/20/2026$275.00Overweight
    Barclays
    AbbVie Inc.
    $ABBV
    1/8/2026Outperform → Peer Perform
    Wolfe Research
    AbbVie Inc.
    $ABBV
    1/7/2026$240.00Neutral
    UBS
    AbbVie Inc.
    $ABBV
    12/10/2025$265.00Hold → Buy
    HSBC Securities
    AbbVie Inc.
    $ABBV
    11/13/2025$280.00Sector Outperform
    Scotiabank
    AbbVie Inc.
    $ABBV
    11/4/2025$237.00Buy → Hold
    DZ Bank
    AbbVie Inc.
    $ABBV
    10/14/2025Buy → Hold
    Erste Group
    More analyst ratings

    $ABBV
    $AKAN
    $CYTO
    $FSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rapp Edward J

    4 - AbbVie Inc. (0001551152) (Issuer)

    4/2/26 5:00:14 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Alpern Robert J

    4 - AbbVie Inc. (0001551152) (Issuer)

    4/2/26 5:00:11 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Quaggin Susan E

    4 - AbbVie Inc. (0001551152) (Issuer)

    4/2/26 5:00:15 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AKAN
    $CYTO
    $FSR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

    6/21/24 4:38:17 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AKAN
    $CYTO
    $FSR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    /C O R R E C T I O N -- AbbVie/

    In the news release, Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®, issued 31-Mar-2026 by AbbVie over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting® First-Time Users Can Claim $400 Off Their First Body Contouring Treatment.*†IRVINE, Calif., March 31, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), announced its fourth annual CoolMonth, featuring exclusive offers on CoolSculpting®, the treatment doctors use most for nonsurgic

    3/31/26 8:05:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

    First-Time Users Can Claim $400 Off Their First Body Contouring Treatment.*†IRVINE, Calif., March 31, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), announced its fourth annual CoolMonth, featuring exclusive offers on CoolSculpting®, the treatment doctors use most for nonsurgical fat reduction.1 Spring is often thought of as a transformative season, making the return of CoolMonth this April a perfect opportunity to reprioritize aesthetic goals. In fact, 50% of people reportedly have considered body contouring treatments (invasive and noninvasive) in pre

    3/31/26 8:05:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie to Host First-Quarter 2026 Earnings Conference Call

    NORTH CHICAGO, Ill., March 31, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its first-quarter 2026 financial results on Wednesday, April 29, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas

    3/31/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AKAN
    $CYTO
    $FSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on AbbVie with a new price target

    RBC Capital Mkts initiated coverage of AbbVie with a rating of Outperform and set a new price target of $260.00

    2/25/26 7:48:26 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on AbbVie with a new price target

    Barclays initiated coverage of AbbVie with a rating of Overweight and set a new price target of $275.00

    2/20/26 8:23:14 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie downgraded by Wolfe Research

    Wolfe Research downgraded AbbVie from Outperform to Peer Perform

    1/8/26 8:35:39 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AKAN
    $CYTO
    $FSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ABBV
    $AKAN
    $CYTO
    $FSR
    SEC Filings

    View All

    SEC Form 424B5 filed by Nkarta Inc.

    424B5 - Nkarta, Inc. (0001787400) (Filer)

    4/3/26 5:29:06 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    4/3/26 4:05:55 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Akanda Corp.

    6-K - AKANDA CORP. (0001888014) (Filer)

    4/2/26 5:25:02 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $ABBV
    $AKAN
    $CYTO
    $FSR
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

    Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth. The update follows a series of key developments, including the successful completion of the first human surgical procedure us

    3/23/26 9:15:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

    SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pursue other opportunities in the oncology space. Dr. Rose has dedicated his career to immunology translational medicine and advancing new treatment options for autoimmune patients. In various leadership roles, he has brought

    6/6/25 8:52:00 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AKAN
    $CYTO
    $FSR
    Financials

    Live finance-specific insights

    View All

    AbbVie to Host First-Quarter 2026 Earnings Conference Call

    NORTH CHICAGO, Ill., March 31, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its first-quarter 2026 financial results on Wednesday, April 29, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas

    3/31/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.73 per share.  The cash dividend is payable May 15, 2026, to stockholders of record at the close of business on April 15, 2026.Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of

    2/19/26 9:37:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

    Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76 Per Share Related to 2025 Acquired IPR&D and Milestones Expense  Delivers Full-Year Net Revenues of $61.160 Billion, an Increase of 8.6 Percent on a Reported Basis and 8.5 Percent on an Operational Basis  Full-Year Global Net Revenues from the Immunology Portfolio Were $30.406 Billion, an Increase of 14.0 Percent on a Reported Basis, or 13.9 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $17.562 Billion; Global Rinvoq Net Revenues Were $8.304 Billion; Global Humira Net Revenues Wer

    2/4/26 7:48:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AKAN
    $CYTO
    $FSR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nkarta Inc.

    SC 13G - Nkarta, Inc. (0001787400) (Subject)

    12/13/24 5:02:47 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

    SC 13G/A - Nkarta, Inc. (0001787400) (Subject)

    11/14/24 4:05:12 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care